Alizea pacemaker. (Image from MicroPort CRM)MicroPort CRM announced that it has received expanded labeling for its line of implantable pacemakers, including Alizea, Borea and Celea.
Shanghai-based MicroPort Inc.'s pacemakers have received an expanded indication for left bundle branch pacing (LBBAP), which the company said is seen as a new approach to physiological pacing, taking advantage of the efficiency of the heart's natural conduction system.
MicroPort designed its Alizea, Borea and Celea pacemakers to be Bluetooth-enabled, and the company says it aimed to make no compromises on the size and battery life of the pacemaker, which is just 11cc in volume and has an expected lifespan of 13 years with all features turned on, including remote monitoring.
The FDA approved Alizea and Celea in May 2023. All three have had the CE mark since January 2021.
New advanced features in the company's latest generation pacemakers include AutoMRI, SafeR Pacing and SAM (Sleep Apnea Monitoring). AutoMRI automatically switches into MRI mode when it detects a magnetic field. The pacemaker can be pre-programmed up to 10 days prior to an MRI scan.
The pacing mode SafeR maintains native AV conduction and effectively reduces unnecessary ventricular pacing. MicroPort states that this mode can reduce the risk of developing AFib, hospitalization due to heart failure, and cardiac death. Meanwhile, SAM reveals largely undiagnosed diseases with serious cardiac complications like AFib.
“Our latest generation of Bluetooth pacemakers integrates advanced DNA features developed over many years with physician support, always with the patient's physiological behavior in mind,” said Vincent Leveaux, vice president of product development and operations at MicroPort CRM. “We are now offering the latest features of the latest physiological pacing technique, (LBBAP). This is the first step in the development of our complete LBBAP solution.”
